News releases from Adaptimmune Therapeutics plc
Positive Opinion for Orphan Drug Designation for ADP-A2M4 in the European Union for the Treatment of Soft Tissue Sarcoma from EMA' Committee of Orphan Medicinal Products
April 28, 2020
Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update
February 27, 2020
Adaptimmune to Report Full Year / Q4 2019 Financial Results and Business Update on Thursday, February 27, 2020
February 20, 2020
Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional American Depositary Shares
February 07, 2020
Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares
January 24, 2020
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
January 21, 2020
Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies
January 14, 2020
Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership
January 13, 2020
Organizational changes strengthen scientific and clinical development from early to late stage, and accelerate application of translational science learnings to therapeutic candidates and trials
Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
January 13, 2020
Regenerative Medicine Advanced Therapy Designation Granted by FDA to ADP‑A2M4 for the Treatment of Synovial Sarcoma
December 03, 2019
Will enable expedited development and review of ADP-A2M4 with the goal of commercialization in 2022 for patients with few other treatment options
Updated Data from Phase 1 ADP-A2M4 Trial Demonstrating Continued Clinical Benefit for People with Synovial Sarcoma
November 16, 2019
Adaptimmune to Report Third Quarter 2019 Financial Results and Business Update on Wednesday, November 6, 2019
November 01, 2019
Adaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmune’s Cell Therapies
October 09, 2019
Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer
October 01, 2019
Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO
September 30, 2019
- Clinical responses in 7 out of 12 patients with synovial sarcoma, and clinical benefit in 11 out 12 patients -
United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4
September 09, 2019
Adaptimmune to Report Second Quarter 2019 Financial Results and Business Update on Thursday, August 1, 2019
July 29, 2019
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will report financial results for the Second Quarter 2019 and provide a business update before the U.S. markets...
Adaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS
July 25, 2019
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, has started its SPEARHEAD-1 trial with ADP-A2M4 SPEAR T‑cells for patients with synovial sarcoma or myxoid/round...
Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center
July 22, 2019
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, has initiated a radiation sub-study of its ADP‑A2M4 trial in collaboration with the University of Texas MD...
Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE‑A4 to Enhance Antitumor Responses
July 18, 2019
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results for the first quarter ended March 31, 2019. Adaptimmune shared a clinical update...
Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors
May 06, 2019
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced significant clinical progress with partial responses in 4 out of 5 synovial sarcoma patients...
Adaptimmune to Present Data Demonstrating that its Off-the-shelf Process Produces T-cells from Stem Cells that Respond to Cancer Targets with a SPEAR TCR at ASGCT Meeting
May 02, 2019
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will present new and compelling data during an oral presentation about its off-the-shelf SPEAR T-cell program at...
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will provide a clinical and business update before the U.S. markets open on Monday May 6, 2019. Following the...